AI 制药是把人工智能应用于新药研发全流程的交叉领域，覆盖靶点发现、分子设计、化合物筛选、性质预测与临床试验设计，核心是用计算预测替代部分湿实验来压缩试错周期，能力包括结构预测、虚拟筛选、性质预测与临床试验优化。它解决的是传统制药研发周期长、成本高、失败率高的问题，并不解决临床阶段的疗效与安全性本身的不可预测性。
AI 制药的核心是用计算压缩试错，它可以帮助企业实现以下目标：
让先导化合物的发现从数年缩短到数月。虚拟筛选在万亿级分子空间中优先排序，实验只在前列候选上进行。结构预测精度提升后，靶点可被快速评估，湿实验资源集中投入到最有希望的候选上。
让结构预测不再依赖耗时实验。蛋白质与分子结构的预测精度提升，靶点可被快速评估。人群分层与终点选择基于真实数据建模，试验规模与周期因此得到优化。
让后期失败在早期被拦截。性质预测把代谢、毒理与溶解性问题前移，减少在临床阶段的淘汰。
让临床试验的设计更精准。人群分层与终点选择基于真实数据建模，试验规模与周期得到优化。
总之，AI 制药可以帮助企业实现新药研发从高投入长周期向数据与计算驱动的转变，把不可承受的搜索空间收敛到可验证的范围，在不改变生物学规律的前提下提升药物发现的效率与成功率。
翻译
AI for drug discovery is the interdisciplinary field applying artificial intelligence across the entire drug development workflow, covering target discovery, molecular design, compound screening, property prediction and clinical trial design. Its core is using computational prediction to replace part of wet-lab iteration and compress trial-and-error cycles, with capabilities covering structure prediction, virtual screening, property prediction and trial optimization. It solves the problems of long cycles, high cost and high failure rates in traditional pharma, but it does not solve the inherent unpredictability of efficacy and safety in the clinical stage.
At the heart of AI drug discovery is compressing trial and error through computation, which can help companies achieve the following:
Shorten lead compound discovery from years to months. Virtual screening prioritizes within a trillion-molecule space, so experiments run only on top candidates.
Remove dependence on slow experiments for structure prediction. Improved prediction of protein and molecular structures allows rapid target evaluation.
Catch late-stage failures early. Property prediction moves metabolism, toxicity and solubility issues forward, reducing clinical attrition.
Make clinical trial design more precise. Cohort stratification and endpoint selection are modeled on real data, optimizing trial size and duration.
In short, AI drug discovery can help enterprises shift new drug development from high-cost long-cycle work toward data- and compute-driven processes, converge an otherwise unmanageable search space into a verifiable range, and improve discovery efficiency and success rates without altering biological reality.
